^
Association details:
| Biomarker: | SMARCA4 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus Chemotherapy and Chemotherapy
Published date:
11/21/2023
Excerpt:
Our study aimed to investigate the efficacy and prognosis of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) in combination with chemotherapy and chemotherapy in patients with stage III-IV SMARCA4-DNSCLC….The difference in median progression-free survival (PFS) between the PD-1 ICIs plus chemotherapy group and the chemotherapy group was statistically significant (9.3 mon vs 6.1 mon, P=0.048).
Secondary therapy:
Chemotherapy
DOI:
10.3779/j.issn.1009-3419.2023.101.26
Source:
Title:
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Published date:
10/16/2023
Excerpt:
CONTRADICTING EVIDENCE: The median PFS under ICB+/- chemotherapy was 4.0 months (CI 95% 2.87- 7.7) vs 7.37 months (CI 95% 6.53-11.3) (p= 0.005) in SMARCA4d versus control, and the median OS was 9.3 months (CI 95% 7.0 – NR) vs 27.6 months (CI 95% 27.3 - NA) (p< 0.0001), respectively....SMARCA4d seems to negatively impact survival outcomes and the efficacy of ICB...
Source:
Title:
The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study
Published date:
08/29/2023
Excerpt:
Forty-seven cases with BRG1-deficient NSCLC were included….Eight patients with advanced tumor stage had received immunotherapy and 4 cases achieved a sustainable clinical response with the disease control rate of 50 %.
DOI:
10.1016/j.anndiagpath.2023.152192
